Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions

NCT ID: NCT02020317

Last Updated: 2015-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

3341 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the impact of reminders for serum potassium monitoring and of hyperkalemia alerts during potassium-increasing drug-drug-interactions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The development of hyperkalemia during potassium-increasing drug-drug-interactions (DDIs) is associated with (i) unknown or elevated serum potassium level at onset of treatment and (ii) insufficient monitoring of serum potassium during therapy. However, potassium-increasing DDIs are frequently started despite an unknown or elevated serum potassium level, and monitoring intervals often exceed 48 hours.

This study investigates the impact of reminders for serum potassium monitoring and hyperkalemia alerts. Both reminders and alerts are displayed in the electronic patient chart of in-patients treated with potassium-increasing DDIs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperkalemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

computer-based reminders and alerts

Behavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)

Group Type ACTIVE_COMPARATOR

decision support in potassium-inc. drug-drug-interactions

Intervention Type BEHAVIORAL

display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts

no computer-based reminders or alerts

Behavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

decision support in potassium-inc. drug-drug-interactions

display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* in-patients treated with concurrent potassium-increasing drugs

Exclusion Criteria

* outpatients; in-patients on wards without computerized physician order entry (i.e. patients treated in the ICU)
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Juerg Blaser, PhD, Prof

Role: PRINCIPAL_INVESTIGATOR

University Hospital Zurich, Center for Clinical Research, Research Center for Medical Informatics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Zurich, Center for Clinical Research, Research Center for Medical Informatics

Zurich, Canton of Zurich, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Eschmann E, Beeler PE, Kaplan V, Schneemann M, Zund G, Blaser J. Patient- and physician-related risk factors for hyperkalaemia in potassium-increasing drug-drug interactions. Eur J Clin Pharmacol. 2014 Feb;70(2):215-23. doi: 10.1007/s00228-013-1597-2. Epub 2013 Oct 23.

Reference Type BACKGROUND
PMID: 24150532 (View on PubMed)

Eschmann E, Beeler PE, Zund G, Blaser J. Evaluation of alerts for potassium-increasing drug-drug-interactions. Stud Health Technol Inform. 2013;192:1056.

Reference Type BACKGROUND
PMID: 23920830 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FZMI-KEK-ZH-Nr. 2013

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Blood Pressure in Dialysis Patients
NCT01421771 COMPLETED NA
The Potassium Supplementation Study
NCT05887622 RECRUITING NA